Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On June 12, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced the FDA approval of prednisolone acetate ophthalmic suspension, with launch planned for Q3 2025.

Prednisolone acetate ophthalmic suspension, USP 1% is a topical, sterile anti-inflammatory agent for ophthalmic use and treatment of steroid-responsive ocular inflammation.

Andy Boyer, Executive Vice President and Chief Commercial Officer, Affordable Medicines, stated that the Affordable Medicines portfolio is growing continuously, with a diverse and strong pipeline supporting “broader access to high-quality treatments across the US healthcare system.”

Boyer also stated that the prednisolone acetate ophthalmic suspension is a complex product to manufacture and develop, and its approval reflects the quality of Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) R&D capabilities and the strength of its supply and manufacturing operations.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that develops pharmaceuticals, with a product portfolio spanning specialty, generics, biosciences, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.

While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.